* Phathom Pharmaceuticals Inc PHAT.OQ reported a quarterly
adjusted loss of $1.39 per share for the quarter ended in
December, lower than the same quarter last year, when the
company reported EPS of $-1.33. The mean expectation of
seven analysts for the quarter was for a loss of $1.08 per
share. Wall Street expected results to range from $-1.52 to -85
cents per share.
* Revenue was $682.00 thousand; analysts expected $412.33
thousand.
* Phathom Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.39.
* The company reported a quarterly loss of $79.57 million.
* Phathom Pharmaceuticals Inc shares had risen by 6.6% this
quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Phathom
Pharmaceuticals Inc is $26.00
This summary was machine generated from LSEG data March 7 at
04:02 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -1.08 -1.39 Missed
Sep. 30 2023 -0.89 -0.76 Beat
Jun. 30 2023 -0.98 -0.84 Beat
Mar. 31 2023 -1.26 -0.89 Beat